Developing a treatment to protect healthcare workers from Marburg virus outbreaks
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control
This study is working on a new treatment to help protect healthcare workers and first responders from the Marburg virus, which can be very dangerous, by using special antibodies that can keep them safe during outbreaks.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project ID | NIH-11077219 on NIH RePORTER |
What this research studies
This research focuses on creating a prophylactic immunotherapy to protect healthcare workers and first responders from Marburg virus disease (MVD), which can cause severe viral hemorrhagic fever with high mortality rates. The approach involves developing highly potent monoclonal antibodies that can be administered in low doses while ensuring long-lasting protection. By targeting the immune response, the goal is to provide a safeguard for those on the front lines during outbreaks, thereby enhancing their safety and the overall effectiveness of outbreak control efforts.
Who could benefit from this research
Good fit: Ideal candidates for this research are healthcare workers and first responders who are at high risk of exposure to the Marburg virus during outbreaks.
Not a fit: Patients who are not involved in healthcare or emergency response roles may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of Marburg virus infection among healthcare workers, ultimately saving lives and maintaining healthcare system stability during outbreaks.
How similar studies have performed: Previous research on prophylactic treatments for Ebola virus has shown promise, indicating that similar approaches for Marburg virus may also be effective.
Where this research is happening
Rockville, United States
- Abvacc, INC. — Rockville, United States (Active)
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.